UCSF is recognized nationally for research on cancer disparities and on the development of cancer control interventions for the multiple ethnic populations that constitute the Northern California region. The scientists responsible for this work have formed the new Society, Diversity and Disparities Program, comprising 28 Members from 15 departments and research units. The broad scientific goal of this program is to reduce the overall cancer burden in our region and disparities in that burden by providing a collaborative, supportive environment for research to enhance the understanding of the determinants of and remedies for disparities. Program themes are: (1) Elucidating the causes and consequences of cancer disparities;(2) developing effective intervention strategies for diverse population sub-groups and settings;and (3) improving diversity among research participants, cancer control researchers, and clinicians. Intra- and inter-program collaborations resulting from establishment of the Society, Diversity and Disparities Program have generated a lively intellectual forum, newly funded grants, a recent Disparities Center application, and several large multi-disciplinary projects under development, including a NCI-Cancer Center/Minority Serving Institution (CCC/MSI U54) proposal. Pilot research is stimulated by the current CCC/MSI U56 and the NCI-funded Asian American Network for Cancer Awareness Research and Training, Redes En Accion Community Network Programs, and the proposed Disparities Center. Interactions between Program Members are facilitated in theme-specific working groups, the Cancer Center's Community Advisory Board meetings and projects, and forums that include an annual retreat and monthly seminars sponsored by Society, Diversity and Disparities and periodically led jointly with the Tobacco Control Program or the Department of Medicine's Medical Effectiveness Research Center for Diverse Populations (MERC)! The Program has $5,416,449 Total peer reviewed support for the last budget year. The Program has 16% intra-programmatic and 38% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-11
Application #
7886661
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
11
Fiscal Year
2009
Total Cost
$58,783
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28

Showing the most recent 10 out of 192 publications